Production (Stage)
Acumen Pharmaceuticals, Inc.
ABOS
$1.02
-$0.01-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -72.29% | 10,009.09% | |||
| Gross Profit | 72.29% | -10,009.09% | |||
| SG&A Expenses | 1.51% | 0.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.30% | 22.72% | |||
| Operating Income | 23.30% | -22.72% | |||
| Income Before Tax | 22.50% | -24.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.50% | -24.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.50% | -24.82% | |||
| EBIT | 23.30% | -22.72% | |||
| EBITDA | 23.31% | -22.74% | |||
| EPS Basic | 23.06% | -24.83% | |||
| Normalized Basic EPS | 23.05% | -24.84% | |||
| EPS Diluted | 23.06% | -24.83% | |||
| Normalized Diluted EPS | 23.05% | -24.84% | |||
| Average Basic Shares Outstanding | 0.74% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.74% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||